NCT04572295 2026-03-11A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast CancerEisai Inc.Phase 1 Active not recruiting51 enrolled
NCT07174336 2026-03-06A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)Eli Lilly and CompanyPhase 3 Recruiting920 enrolled